trending Market Intelligence /marketintelligence/en/news-insights/trending/F2fJAg5C7phibW1iN8AF-A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AstraZeneca to sell Arimidex, Casodex rights in parts of Europe, Africa

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

AstraZeneca to sell Arimidex, Casodex rights in parts of Europe, Africa

AstraZeneca PLC is selling rights to its breast cancer medicine Arimidex and prostate cancer drug Casodex in parts of Europe, Africa and certain other countries to Laboratoires Juvise Pharmaceuticals SAS for $181 million up front.

As part of the deal, the French healthcare distributor will also make sales-related milestone payments of up to $17 million to AstraZeneca.

Under the agreement, privately held Villeurbanne, France-based Juvise Pharmaceuticals will gain rights to Arimidex and Casodex in certain European countries, including Belgium, Finland, France, Germany, Ireland, Spain, Switzerland and the Netherlands.

The deal also covers African countries like Cameroon, Guinea, Mali, Mauritania, Togo and the Democratic Republic of the Congo.

"Today's agreement is part of a broader strategy of reducing our portfolio of mature medicines to reallocate resources towards developing our pipeline of new medicines," Dave Fredrickson, executive vice president of AstraZeneca's oncology business unit, said in a Dec. 20 press release.

The Cambridge, U.K.-based drugmaker sold rights to Arimidex and Casodex in the U.S. in 2017. The therapies generated about $37 million and $24 million, respectively, in sales in the countries covered under the agreement in 2018, the company said.